Category: Issue 3 (July-September)33

Unresolved issues, dilemmas and points of interest in thyroid cancer: A current perspective

Posted on by

Nicholas J Sarlis, Loukas Gourgiotis

Download PDF

Thyroid cancer (TC) is the commonest endocrine malignancy. In the overwhelming majority of cases, thyroid carcinomas are well-differentiated malignancies that respond favorably to treatment; however, this outcome cannot be absolutely guaranteed. The absence of large prospective randomized clinical trials in TC—due to its low incidence and protracted clinical course in cases with persistent/recurrent metastatic disease—results in considerable debates regarding the optimal treatment and follow-up regimens in this malignancy…

The role of estrogens in cardiovascular disease in the aftermath of clinical trials

Posted on by

Lambrini Gouva, Agathocles Tsatsoulis

Download PDF

The effects of estrogens on reproductive tissues and climacteric symptoms are unambiguous. However, their effects on other tissues and, in particular, the cardiovascular system remain controversial. In general, premenopausal women are protected from coronary heart disease (CHD) compared with aged-matched men but this `female protection’ appears to be lost after menopause, suggesting beneficial effects of female sex hormones on the cardiovascular system…

Glucocorticoids and bone: cellular, metabolic and endocrine effects

Posted on by

Mauro Doga, Stefania Bonadonna, Andrea Giustina

Download PDF

Chronic exposure to excessive concentrations of endogenous cortisol or to pharmacologic doses of glucocorticoids (GCs) causes multiple deleterious effects on body structure and function. Osteopenia, osteoporosis and bone fractures are well recognized consequences of excessive GC exposure, with fractures being a major cause of morbidity and mortality, particularly in the elderly. In particular, GCs have profound effects on bone metabolism, acting at many sites…

The effect of long-term somatostatin analogue treatment on free and total insulin-like growth factor (IGF) -I, -II and IGF binding protein -1, -2 and -3 serum levels in euthyroid patients with active thyroid eye disease

Posted on by

Gerasimos Krassas, Nikolaos Pontikides, Argyrios Dumas, Jan Frystyk, Jian-WenChen, Allan Flyvbjerg

Download PDF

The aim of this study was to investigate the effect of long-term somatostatin analogue (SM-a) treatment on serum levels of free (F) and total (T) insulin-like growth factor (IGF)-I, -II and IGF binding protein (IGFBP) – 1, -2 and -3 in euthyroid patients with active thyroid ophthalmopathy. For this purpose, we measured the above-mentioned parameters …

The concurrence of Microalbuminuria and Retinopathy with Cardiovascular Risk Factors; reliable predictors of Asymptomatic Coronary Artery Disease in Type 2 Diabetes

Posted on by

George Ioannidis, Melpomeni Peppa, Phivi Rontogianni, Michael Callifronas, Christos Papadimitriou, Georgia Chrysanthopoulou, Lambros Anthopoulos, Matina Kesse, Nicolaos Thalassinos

Download PDF

People with diabetes mellitus type 2 (DM2) have a greater risk for premature morbidity and mortality due to cardiovascular disease than the general population: cardiovascular disease accounts for 75% of deaths in this population group. We examined whether or not the association of clinical cardiovascular risk factors (RF) with both …

Growth hormone deficiency associated with moyamoya disease in a 16 year-old boy

Posted on by

Maria Kalina, Barbara Kalina-Faska, Katarzyna Wojaczynska-Stanek, Ewa Malecka-Tendera, Elzbieta Marszal

Download PDF

Moyamoya disease is a rare cerebrovascular disorder which, according to a few literature reports, can coexist with hypothalamic-pituitary dysfunction. We report a 16 year-old boy referred to our Department because of short stature and headaches. He additionally, at admission, presented discrete facial dysmorphy, bruxism, luxation of temporomandibular joint …